268 related articles for article (PubMed ID: 26408169)
1. Endocannabinoids and the Cardiovascular System in Health and Disease.
O'Sullivan SE
Handb Exp Pharmacol; 2015; 231():393-422. PubMed ID: 26408169
[TBL] [Abstract][Full Text] [Related]
2. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.
Montecucco F; Di Marzo V
Trends Pharmacol Sci; 2012 Jun; 33(6):331-40. PubMed ID: 22503477
[TBL] [Abstract][Full Text] [Related]
3. The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism?
Steffens S; Pacher P
Curr Drug Targets; 2015; 16(4):334-41. PubMed ID: 25469884
[TBL] [Abstract][Full Text] [Related]
4. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
[TBL] [Abstract][Full Text] [Related]
5. Role of endocannabinoids in cardiovascular shock.
Malinowska B; Lupinski S; Godlewski G; Baranowska U; Schlicker E
J Physiol Pharmacol; 2008 Dec; 59 Suppl 8():91-107. PubMed ID: 19258666
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoids and Mental Disorders.
Rubino T; Zamberletti E; Parolaro D
Handb Exp Pharmacol; 2015; 231():261-83. PubMed ID: 26408164
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
10. The evolution and comparative neurobiology of endocannabinoid signalling.
Elphick MR
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3201-15. PubMed ID: 23108540
[TBL] [Abstract][Full Text] [Related]
11. Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.
Martín Giménez VM; Noriega SE; Kassuha DE; Fuentes LB; Manucha W
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):177-190. PubMed ID: 29764302
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
Tam J
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
14. Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes.
Lu Y; Akinwumi BC; Shao Z; Anderson HD
J Cardiovasc Pharmacol; 2014 Nov; 64(5):420-30. PubMed ID: 24979612
[TBL] [Abstract][Full Text] [Related]
15. Interactions Between Alcohol and the Endocannabinoid System.
Kunos G
Alcohol Clin Exp Res; 2020 Apr; 44(4):790-805. PubMed ID: 32056226
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
17. The Peripheral Cannabinoid Receptor Type 1 (CB
O'Sullivan SE; Yates AS; Porter RK
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684760
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
Pertwee RG
AAPS J; 2005 Oct; 7(3):E625-54. PubMed ID: 16353941
[TBL] [Abstract][Full Text] [Related]
19. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart.
Hajrasouliha AR; Tavakoli S; Ghasemi M; Jabehdar-Maralani P; Sadeghipour H; Ebrahimi F; Dehpour AR
Eur J Pharmacol; 2008 Jan; 579(1-3):246-52. PubMed ID: 17950273
[TBL] [Abstract][Full Text] [Related]
20. The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?
Oppong-Damoah A; Gannon BM; Murnane KS
CNS Neurol Disord Drug Targets; 2022; 21(1):3-13. PubMed ID: 33573565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
